活力系统与临卡洛在慢性异常性便秘中的成本效益
Jeffrey D Voigt1, Christine L Frissora2
1Medical Device Consultants of Ridgewood, Ridgewood, NJ, USA. meddevconsultant@aol.com.
Advances in therapy
|November 11, 2024
概括
活力系统为慢性异常性便秘 (CIC) 提供了具有成本效益的治疗方法,改善了生活质量 (QoL) 并降低了与林纳克洛相比的整体医疗费用.
科学领域:
- 胃肠病学 胃肠病学
- 卫生经济学 卫生经济学
- 临床结果研究研究
背景情况:
- 慢性异常性便秘 (CIC) 影响到8-12%的美国人口,有显著的未满足的需求和患者/医生对当前治疗不满.
- CIC对患者的生活质量 (QoL) 有负面影响.
- 目前对CIC的药理疗法存在局限性,导致需要替代治疗选择.
研究的目的:
- 为了比较Vibrant系统的总成本和经质量调整的寿命年 (QALYs) 与1至3年的CIC治疗中利纳克洛提德的总成本.
- 评估与每个治疗相关的直接 (D) 和间接 (I) 成本.
- 评估活力系统的长期经济和临床益处.
主要方法:
- 马尔科夫模型被用来预测1-3年的美国成本和QALY,比较Vibrant系统与linaclotide.
- 直接成本包括产品清单价格和不良事件医疗成本.
- 间接成本 (缺勤,出席) 被纳入第二个模型,利用现实世界持久性数据.
主要成果:
- 与林纳克洛提德相比,活跃系统的直接成本较低,在1-3年内改善了QALY.
- 累积分析显示,在12个月及之后,成本节约在345美元至3866美元之间,以及效率提高.
- 活力系统治疗导致改善健康结果和减少整体经济负担.
结论:
- 活跃系统为CIC管理提供了一个有利的形象,成本较低,QALY优越.
- 这些发现支持将活力系统视为CIC的第一线治疗方法.
- 由于其经济和临床优势,保险公司应该考虑对活力系统进行覆盖.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186
Drugs Affecting GI Tract Motility: Other Laxatives
170
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
170
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212
Inflammatory Bowel Disease V: Surgical Management
122
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
122


